Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Actinium Pharmaceuticals Inc
ATNM | US
1.78
USD-0.04
-2.20%
ATNM | US
About Actinium Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.78
Open
1.82
High
1.83
Low
1.76
Actinium Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes including Actinium-225 Iodine-131 and Lutetium-177 directed at multiple targets in oncology and hematology including CD45 CD33 HER3 and other. It has collaboration with Astellas Pharma Inc. to develop theranostics for solid tumor indications; EpicentRx Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York New York.
View LessATNM | US
Risk
67.3
Sharpe
-0.70
Luna's Score
48/100
Recommendation
Hold
Luna says (ATNM | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
79.3%1 month
67.3%3 months
155.6%6 months
119.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
6.84
Price to book
1.29
Debt to equity
0.04
Debt to assets
0.02
Ent. to EBITDA
-3.62
Ent. to rev.
1.73K
PEG
-
Other Fundamentals
EBITDA
-46.48M
MarketCap
55.45M
MarketCap(USD)
55.45M
Div. yield
-
Op. margin
-57.67K
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-87.96
Short ratio
5.97
Short perc.
6.32
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.36
Range1M
0.45
Range3M
7.31
Volumes: Market Activity
Rel. volume
0.71
Price X volume
346.06K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.62 | - | Cheaper |
| Ent. to Revenue | 1,726.07 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.29 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 155.59 | - | Riskier |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 55.45M | - | Emerging |
